Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

NeurologyLive® Staff

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

March 26th 2022

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

NeurologyLive® Staff

March 19th 2022

Neurology News Network for the week ending March 19, 2022.

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

NeurologyLive® Staff

March 12th 2022

Neurology News Network for the week ending March 12, 2022. [WATCH TIME: 4 minutes]

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

NeurologyLive® Staff

February 26th 2022

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

NeurologyLive® Staff

February 19th 2022

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

NeurologyLive® Staff

February 12th 2022

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

NeurologyLive® Staff

February 5th 2022

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

NeurologyLive® Staff

January 29th 2022

Neurology News Network for the week ending January 29, 2022.

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

NeurologyLive® Staff

January 22nd 2022

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

NeurologyLive® Staff

January 15th 2022

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

NeurologyLive® Staff

January 8th 2022

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Neurology News Network: Top FDA Approvals of 2021

Neurology News Network: Top FDA Approvals of 2021

NeurologyLive® Staff

January 1st 2022

Neurology News Network for the week ending January 1, 2022. [WATCH TIME: 4 minutes]

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

December 25th 2021

Neurology News Network for the week ending December 25, 2021.

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

NeurologyLive® Staff

December 18th 2021

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

$Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients$

Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients

NeurologyLive® Staff

December 11th 2021

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

NeurologyLive® Staff

December 4th 2021

Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

NeurologyLive® Staff

November 27th 2021

Neurology News Network for the week ending November 27, 2021.

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

NeurologyLive® Staff

November 20th 2021

Neurology News Network for the week ending November 20, 2021.

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

NeurologyLive® Staff

November 13th 2021

Neurology News Network for the week ending November 13, 2021.

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

NeurologyLive® Staff

November 6th 2021

Neurology News Network for the week ending November 6, 2021.

Ocrelizumab Safety Profile in Elders, Phase 3b CASTING Trial Results, Cannabis Information Sources for MS

NeurologyLive® Staff

October 30th 2021

Neurology News Network for the week ending October 30, 2021.

Cenobamate Provides Long-Term Seizure Reduction, Nerivio's Impact in Chronic Migraine, Weekly Episodes Reduced With FT218

Cenobamate Provides Long-Term Seizure Reduction, Nerivio's Impact in Chronic Migraine, Weekly Episodes Reduced With FT218

NeurologyLive® Staff

October 23rd 2021

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Alemtuzumab Treatment Poplation Identified, Siponimod Preserves Retinal Thickness, ATA188 Shows Success in Phase 1

Alemtuzumab Treatment Poplation Identified, Siponimod Preserves Retinal Thickness, ATA188 Shows Success in Phase 1

NeurologyLive® Staff

October 16th 2021

Neurology News Network for the week ending October 15, 2021. [WATCH TIME: 3 minutes]

XEN1101 Demonstrates Efficacy in Focal Epilepsy, Long-Term Profile of Inebilizumab, Combination of Epilepsy and MS Progress Worse

NeurologyLive® Staff

October 9th 2021

Neurology News Network for the week ending October 9, 2021. [WATCH TIME: 3 minutes]

Study of P2B001 in PD Concludes, Verdiperstat Fails in MSA, Fenfluramine sNDA Submitted for LGS

Study of P2B001 in PD Concludes, Verdiperstat Fails in MSA, Fenfluramine sNDA Submitted for LGS

October 2nd 2021

Neurology News Network for the week of October 2, 2021. [WATCH TIME: 4 minutes]

Noncontact Boxing Improves Movement in Parkinson, Riluzole's Lack of Effect in Spincerebellar Ataxia, Positive Impact of Cannabis in Dystonia

Noncontact Boxing Improves Movement in Parkinson, Riluzole's Lack of Effect in Spincerebellar Ataxia, Positive Impact of Cannabis in Dystonia

NeurologyLive® Staff

September 25th 2021

Neurology News Network for the week ending September 25, 2021. [WATCH TIME: 4 minutes]

AMX0035 NDA Planned, gammaCore Approved to Treat Paroxysmal Hemicrania, Epilepsy Represents Risk Factor for SUD

AMX0035 NDA Planned, gammaCore Approved to Treat Paroxysmal Hemicrania, Epilepsy Represents Risk Factor for SUD

September 18th 2021

Neurology News Network for the week ending September 18, 2021.

Joint Mobilization Exercises Improve Systemic Sclerosis Spasticity, Ocrelizumab Long-Term Safety, Antiplatelets Non-Effect on Recurrent ICH

Joint Mobilization Exercises Improve Systemic Sclerosis Spasticity, Ocrelizumab Long-Term Safety, Antiplatelets Non-Effect on Recurrent ICH

NeurologyLive® Staff

September 11th 2021

Neurology News Network for the week ending September 11, 2021.

Salt Substitutes Reduce Stroke Risk, Access to Rehab Disrupted by COVID-19, Headache Infusion Centers Limited

Salt Substitutes Reduce Stroke Risk, Access to Rehab Disrupted by COVID-19, Headache Infusion Centers Limited

NeurologyLive® Staff

September 4th 2021

Neurology News Network for the week ending September 4, 2021.

<1 2 3 4 5 6 7 8 9 10 >

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.